DAWN Fundamental Analysis - DAY ONE BIOPHARMACEUTICALS I

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to DAWN. DAWN was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DAWN as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, DAWN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

DAWN had negative earnings in the past year.

In the past year DAWN has reported a negative cash flow from operations.

In the past 5 years DAWN always reported negative net income.

In the past 5 years DAWN always reported negative operating cash flow.

1.2 Ratios

DAWN's Return On Assets of -18.30% is fine compared to the rest of the industry. DAWN outperforms 77.80% of its industry peers.

Looking at the Return On Equity, with a value of -20.61%, DAWN belongs to the top of the industry, outperforming 84.14% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-18.3%
ROE	-20.61%
ROIC	N/A

ROA(3y)-35.78%

ROA(5y)-50.98%

ROE(3y)-38.78%

ROE(5y)-56.84%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

DAWN's Gross Margin of 94.02% is amongst the best of the industry. DAWN outperforms 93.66% of its industry peers.

DAWN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	94.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.

DAWN has more shares outstanding than it did 1 year ago.

DAWN has more shares outstanding than it did 5 years ago.

There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

DAWN has an Altman-Z score of 6.89. This indicates that DAWN is financially healthy and has little risk of bankruptcy at the moment.

DAWN has a better Altman-Z score (6.89) than 77.24% of its industry peers.

DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.89

ROIC/WACCN/A

WACC9.32%

2.3 Liquidity

DAWN has a Current Ratio of 9.65. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.

DAWN has a better Current ratio (9.65) than 80.04% of its industry peers.

A Quick Ratio of 9.53 indicates that DAWN has no problem at all paying its short term obligations.

DAWN has a Quick ratio of 9.53. This is amongst the best in the industry. DAWN outperforms 80.22% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.65
Quick Ratio	9.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.38% over the past year.

DAWN shows a strong growth in Revenue. In the last year, the Revenue has grown by 2190.50%.

EPS 1Y (TTM)15.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-480%

Revenue 1Y (TTM)2190.5%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%313.92%

3.2 Future

The Earnings Per Share is expected to grow by 24.09% on average over the next years. This is a very strong growth

Based on estimates for the next years, DAWN will show a very strong growth in Revenue. The Revenue will grow by 36.00% on average per year.

EPS Next Y29.63%

EPS Next 2Y24.32%

EPS Next 3Y25.91%

EPS Next 5Y24.09%

Revenue Next Year18.56%

Revenue Next 2Y32.64%

Revenue Next 3Y35.16%

Revenue Next 5Y36%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 25.91% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.32%

EPS Next 3Y25.91%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

DAWN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (10/17/2025, 6:08:04 PM)

After market: 7.2 0 (0%)

7.2

-0.27 (-3.61%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-05 2025-08-05/amc

Earnings (Next)10-20 2025-10-20/bmo

Inst Owners85.34%

Inst Owner Change-0.01%

Ins Owners2.32%

Ins Owner Change0.3%

Market Cap737.50M

Analysts82.5

Price Target23.72 (229.44%)

Short Float %13.2%

Short Ratio7.48

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)21.39%

Min EPS beat(2)20.33%

Max EPS beat(2)22.45%

EPS beat(4)3

Avg EPS beat(4)-4.75%

Min EPS beat(4)-73.33%

Max EPS beat(4)22.45%

EPS beat(8)5

Avg EPS beat(8)9.07%

EPS beat(12)9

Avg EPS beat(12)6.89%

EPS beat(16)10

Avg EPS beat(16)1.6%

Revenue beat(2)0

Avg Revenue beat(2)-3.05%

Min Revenue beat(2)-5.83%

Max Revenue beat(2)-0.26%

Revenue beat(4)1

Avg Revenue beat(4)-4.88%

Min Revenue beat(4)-16.43%

Max Revenue beat(4)3.01%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-16.54%

EPS NQ rev (1m)0%

EPS NQ rev (3m)12.94%

EPS NY rev (1m)0.34%

EPS NY rev (3m)10.94%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-5.68%

Revenue NY rev (1m)0.24%

Revenue NY rev (3m)-4.25%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.93
P/FCF	N/A
P/OCF	N/A
P/B	1.6
P/tB	1.67
EV/EBITDA	N/A

EPS(TTM)-1.65

EYN/A

EPS(NY)-0.81

Fwd EYN/A

FCF(TTM)-0.67

FCFYN/A

OCF(TTM)-0.62

OCFYN/A

SpS1.83

BVpS4.5

TBVpS4.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.3%
ROE	-20.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	94.02%
FCFM	N/A

ROA(3y)-35.78%

ROA(5y)-50.98%

ROE(3y)-38.78%

ROE(5y)-56.84%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.36

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	177.31%
Cap/Sales	3.18%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.65
Quick Ratio	9.53
Altman-Z	6.89

F-Score6

WACC9.32%

ROIC/WACCN/A

Cap/Depr(3y)352.72%

Cap/Depr(5y)301.63%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)15.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-480%

EPS Next Y29.63%

EPS Next 2Y24.32%

EPS Next 3Y25.91%

EPS Next 5Y24.09%

Revenue 1Y (TTM)2190.5%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%313.92%

Revenue Next Year18.56%

Revenue Next 2Y32.64%

Revenue Next 3Y35.16%

Revenue Next 5Y36%

EBIT growth 1Y61.8%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year24.31%

EBIT Next 3Y17.93%

EBIT Next 5YN/A

FCF growth 1Y45.71%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.32%

OCF growth 3YN/A

OCF growth 5YN/A

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens